Globalworld globe
United Kingdom
North America
Europe
  • facebook
  • linkedin
Medical Developments International
  • Home
  • Products
    • Asthma & COPD
    • Penthrox
  • About
    • Distributor Information
    • Careers
    • Associations
  • Investors/Media
    • Financial Reports
    • Board of Directors/Management
    • Corporate Governance
    • Media Centre
    • Diversity Policy
    • Share Trading Policy
  • Healthcare Professionals
  • Contact

News

Chairman’s and CEO’s Report

Feb 25, 2013AaronNews

Download CEO’s & Chairman’s Report as PDF

RECORD PROFIT STRONG GROWTH AND 3 CENTS FULLY FRANKED INTERIM DIVIDEND

Medical Developments International Ltd. (ASX:MVP) delivered a Record Net Profit After Tax of $1,444,000 for the half year ended 31 December 2012, which represents a 25% increase on H1FY2012 ($1,156,000).

The financial result represents:

  • 23% increase in Sales to $6,482,000
  • 23% increase in Earnings before interest and tax to $1,951,000
  • 165% increase in Sales of Asthma Devices in Australia
  • 109% increase in Sales of Asthma Devices Internationally
  • 66% increase in Sales from Medical Devices
  • 267% increase in Sales of Penthrox to GP’s and Hospitals

KEY ACHIEVEMENTS

  • Completed the Penthrox Phase III Pivotal Clinical Trial.  All Endpoints successfully met
  • Won tender to exclusively supply GSK Australia with Asthma devices
  • Won international tender to exclusively supply Canadian Hospitals with Asthma devices
  • Obtained approval from UK authorities to reimburse the cost of Space Chambers
  • Established European Head Office
  • Appointed distributors in Europe and Asia for Asthma devices
  • Lodged application with the FDA to approve Asthma devices for sale in the USA
  • Signed a research and development program with CSIRO for the manufacture of Penthrox
  • Growth in New Zealand, GCC and the Middle East in Penthrox
  • Australian growth in Penthrox in ‘Doctors Bag’ and Hospital business for Penthrox
  • Ongoing success and focus on improvements in manufacturing efficiency
  • Completed Royal Adelaide Hospital trial for use of Penthrox in Colonoscopy

Contact Us

for information on our range of products

Find a distributor

in our global network

Investors

invest in a company with
innovative foresight

News

  • Green Whistle gets the Green Light – FDA clears US Penthrox clinical trial

    2 March 2022 ASX ANNOUNCE...

  • MVP FY22 Half Year Results Investor Presentation

    25 February 2022 ASX anno...

  • MVP FY22 Half Year Report and Accounts

    24 February 2022 ASX Anno...

Healthcare Professional Registration

Login to access healthcare professional resources



Remember Me

Forgot password? | Register

Medical Developments International

Address:
4 Caribbean Drive, Scoresby,
Victoria, 3179
Australia
Phone: +61 3 9547 1888
Email: [email protected]
ABN: 14 106 340 667
For Medical Enquiries:

Phone: 1800 PENTHROX (1800 736 847)
Email: [email protected]

Email Newsletter